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Target population in Spain is estimated at 500,000 patients and
15% of those receive a monoterapia drug treatment for acute
bipolar mania. Nowadays, when considering drug costs, direct
medical costs and adverse events treatment, average annual cost
per treated patient in Spain is estimated at €4006 and it is likely
to be estimated at €4039 after the introduction of ziprasidone.
Sensibility analysis showed that at a constant market share of
24% for the forecasted three years, then the introduction of
ziprasidone is not likely to have any economic impact on the
Spanish National Pharmaceutical budget. CONCLUSIONS:
This budget impact model shows that the introduction of ziprasi-
done is likely to have minimal impact on acute bipolar mania
medication costs in Spain. Current drug costs due to acute
bipolar mania were estimated at €908 millions for the next 3
years and at €916 millions after the introduction of ziprasidone.
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ADHD is a common disorder of childhood and adolescence in
the US and Europe. The NIMH MTA Study is a clinical land-
mark trial, including 579 children age 7–9.9 years with ADHD
according to DSM-IV criteria, who were randomly assigned to
14 months of medication management (MedMgt), intense behav-
ioral treatment (Beh), both combined (Comb), or community care
(CC). OBJECTIVE: To evaluate the cost-effectiveness of clinically
proven treatment strategies (neither placebo nor single drugs) for
ADHD and Hyperkinetic Disorder (HKD/HKCD, a subgroup
meeting ICD-10-based diagnostic criteria used in Europe) in ﬁve
countries, using patient-level data from the MTA Study over 14
months. METHODS: Medical resource utilization data came
from the MTA, excluding its research component. Unit costs (year
2005) were calculated from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, UK,
and USA. Corresponding to the primary study endpoint, treat-
ment response was deﬁned as normalization of core symptoms
(SNAP-IV teacher/parent scores <1). Utility estimates were
derived from expert estimates and parent-proxy-ratings.
RESULTS: Incremental cost-effectiveness ratios (ICERs) were
determined for the total study population and subgroups with
pure ADHD (without comorbidity, n = 184), pure HKD (n = 77),
or HKD/HKCD (n = 145). ICERs per additional patient “nor-
malized” ranged from to dominance to €4200 for MedMgt versus
CC and from €21,000 to €100,000 for Comb versus MedMgt.
MedMgt dominated Beh and exhibited extended dominance over
CC compared to a hypothetical “Do Nothing” alternative.
Results were supported by cost-effectiveness acceptability and
sensitivity analyses. CONCLUSIONS: Despite international dif-
ferences regarding standards of care, diagnostic criteria, and unit
costs, key ﬁndings for European jurisdictions were consistent with
US results. Although cost-utility estimates for this pediatric pop-
ulation should be interpreted with caution, results indicate accept-
able to attractive cost-effectiveness of an intense MedMgt
strategy. Further analyses will have to explore the impact of psy-
chiatric comorbidity and broader clinical endpoints.
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Beyond disease-deﬁning core symptoms of inattention, hyperac-
tivity, and impulsivity, ADHD is characterized by functional
impairment of patients. The Columbia Impairment Scale (CIS) is
a parent rating scale with relatively strong psychometric prop-
erties, tapping four major dimensions: interpersonal relations,
psychopathology, schoolwork, and use of leisure time. OBJEC-
TIVES: CIS ratings from the NIMH MTA Study (n = 579 chil-
dren with ADHD according to DSM-IV-criteria) were used as an
alternative outcome measure to evaluate the cost-effectiveness of
medication management (MedMgt), intense behavioral treat-
ment (Beh), both combined (Comb), or community care (CC) in
the study population and in three subgroups: hyperkinetic dis-
order (according to ICD-10-criteria preferred in Europe); pure
HKD or HKD/HKCD, and in pure ADHD, over 14 months.
METHODS: For costing (societal and third-party payer’s per-
spectives), patient-level resource utilization data were combined
with country-speciﬁc unit costs for Germany, The Netherlands,
Sweden, UK, and United States (year 2005). Incremental cost-
effectiveness ratios (ICERs) were determined using functional
improvement (CIS effect size [ES], Cohen’s d) as clinical outcome
criterion. Four treatment strategies and a hypothetical “Do
Nothing” alternative were compared with each other. RESULTS:
The four MTA treatment strategies were all clinically effective.
Across jurisdictions, both CC versus “Do Nothing” (ICERs
ranging from €1200/ES to €2600/ES) and MedMgt (ICERs
versus “Do Nothing” from €1000/ES to €2700/ES, ICERs versus
CC from dominance to €3000/ES) appeared attractive on
grounds of cost-effectiveness. MedMgt dominated Beh, and
ICERs for Comb versus MedMgt ranged from €500,000/ES to
€1,000,000/ES. Results for subgroups with pure ADHD,
HKD/HKCD, and pure HKD were broadly similar. Sensitivity
analyses including probabilistic evaluations using non-paramet-
ric bootstrapping supported these ﬁndings. CONCLUSIONS:
Despite notable international differences in terms of diagnostic
criteria, standards of care, and unit costs, the cost-effectiveness
of MTA-based clinical treatment strategies for patients with pure
ADHD seemed remarkably similar across jurisdictions. The
impact of comorbidity remains to be explored.
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OBJECTIVE: In light of recent clinical evidence, the indication
of the NMDA antagonist memantine has been extended to
“moderate to severe Alzheimer’s disease (AD)”. No pharmaco-
economic evaluation has been performed in this indication to
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date. This study provides an estimate of the cost-effectiveness of
memantine compared with standard care (no pharmacotherapy)
in moderate to severe AD adapted to a Canadian setting and
including all available evidence. No other pharmacological treat-
ment was included in the evaluation as memantine is currently
the only drug approved in this indication. METHODS: The pro-
gression of AD in terms of cognitive severity, functional dis-
ability and mortality was simulated over two-years using a 
state-transition (Markov) model. Outcomes of the model were
Quality-Adjusted Life-Years (QALY) and costs from a societal
perspective. The main cost and epidemiological input parame-
ters of the model were computed using data from the Canadian
Study on Health and Aging (CSHA). All relevant published and
unpublished clinical trials of memantine versus placebo in mod-
erate to severe AD were used to compute the transition proba-
bilities between health states. A priori distributions were
associated to all relevant parameters in order to enable stochas-
tic analyses. RESULTS: Compared with standard care, the
memantine strategy produced 0.03 additional QALYs, with no
additional overall cost. Probabilistic sensitivity analyses give
83.3% chance that memantine treatment is cost neutral, 89.5%
chance of being cost-effective if the decision-maker is willing to
pay $20,000 for a quality-adjusted life year and 96.2% chance
for a willingness-to-pay of $100,000 per QALY. Robustness of
the results was conﬁrmed through one-way and scenario-based
sensitivity analyses. CONCLUSIONS: Our evaluation found
memantine dominant over standard care. Results were compa-
rable with those published for acetylcholinesterase inhibitors
indicated for treatment of earlier stages of AD.
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OBJECTIVE: To determine cost-effectiveness of antidepressant
groups (SNRIs, SSRIs, and TCAs) in treating major depressive
disorder (MDD) over a 6-month time horizon from the view-
point of the Brazilian Ministry of Health. METHODS: An exist-
ing decision tree model developed by our group was adapted to
Brazil, based on Brazilian treatment guidelines. Clinical data
were obtained from a published meta-analysis of remission rates
published by Machado et al. Patients included adults >= 18 with
MDD, diagnosed using DSM-III/IV or comparable, with moder-
ate-to-severe disease (HAMD >= 15 or MADRS >= 18), without
comorbidities or comedications, and followed by >= 6 weeks of
treatment. Treatments included: SNRIs (venlafaxine, duloxetine,
milnacipran), SSRIs (citalopram, escitalopram, ﬂuoxetine,
paroxetine, sertraline) and/or TCAs (clomipramine, amitripty-
line, nortriptyline, imipramine). SSRIs were used as secondary
treatment for SNRIs and TCAs, TCAs were used as secondary
treatment for SSRIs. Clinical outcome was remission, deﬁned as
a ﬁnal HAMD score <= 7 or MADRS <= 12. Included were all
direct costs of treatment (drug, physician visits, hospitalization).
Drug costs were obtained from the 2006 Brazilian National Drug
Price List. Costs of hospitalizations and physician visits were
taken from the 2006 Health care System database (DATASUS).
All costs were presented in undiscounted 2006 Brazilian Reais
(1R$ = USD$0.46). Univariate and Monte Carlo sensitivity
analyses were performed. RESULTS: The primary ITT remission
rate of SNRIs was signiﬁcantly (P < 0.05) higher than SSRIs and
TCAs. Expected costs/patient treated were: SNRIs = R$4698;
SSRIs = R$5341; TCAs = R$4867. Overall success rates (primary
+ secondary treatment across all decision tree branches) were:
SNRIs = 78.1%; SSRIs = 74.0%; TCAs = 76.4%. Average
costs/success were: SNRIs = R$6017; SSRIs = R$7217; TCAs =
$6368. Monte Carlo analysis conﬁrmed the relative positions.
Break-even analysis showed that results were sensitive to varia-
tions to primary success rates. CONCLUSIONS: SNRIs domi-
nated the other two antidepressant classes. Using SNRIs on
average could save the government R$775 million annually.
Further analyses are warranted to conﬁrm results since they were
sensitive to primary remission rates.
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OBJECTIVES: Economic models have demonstrated the cost-
effectiveness of escitalopram versus citalopram in major depres-
sive disorder (MDD), but no head-to-head clinical trials have
evaluated their cost-effectiveness to date. The objective of this
study was to assess the relative cost-effectiveness of escitalopram
compared with citalopram in outpatients with MDD.
METHODS: An economic evaluation was conducted alongside
a double-blind randomized clinical trial conducted by French
general practitioners and psychiatrists, comparing ﬁxed doses of
escitalopram (20 mg/day) or citalopram (40 mg/day) over 8
weeks in outpatients with MDD (baseline Montgomery-Åsberg
Depression Rating Scale (MADRS) score ≥30). A standardised
health care services form was used to record physician visits, hos-
pitalisations, treatments and days of sick leaves for the 2-month
pre-study period and the 8-week study period. RESULTS: Sta-
tistically signiﬁcant improvements in remission rates were
observed in patients treated with escitalopram (56% vs. 43%, 
p < 0.05). Using the price of the generic citalopram, mean per-
patient costs from a health care perspective for the escitalopram
group were 45% lower than the citalopram group (€79 vs. €144;
p < 0.05). Differences were mostly related to lower hospitalisa-
tion costs. Bootstrapped distributions of the cost-effectiveness
ratios also showed better effectiveness and lower costs for esci-
talopram compared with citalopram with more than 85% of 
the draws located in the southeastern quadrant of the cost-
effectiveness plan, indicating that escitalopram was the dominant
strategy. Sensitivity analyses conﬁrmed the dominance of esci-
talopram over citalopram from a payer perspective. CONCLU-
SIONS: Escitalopram is signiﬁcantly more effective than
citalopram and is associated with lower health care costs. This
prospective economic analysis demonstrated that escitalopram is
a cost-effective ﬁrst-line treatment option for MDD.
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OBJECTIVES: Despite progress in the treatment of schizophre-
nia following the introduction of atypical antipsychotics in the
late 1990s, current pharmacological options still carry limita-
tions, as highlighted in a recent, pragmatic study in the US.
Sertindole is an atypical antipsychotic with a good tolerability
proﬁle likely to favour long-term adherence, reductions in
relapse and re-hospitalisation rates, and improvements in overall
